The 3 most recent market catalysts affecting $PULM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 65
Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
Pulmatrix's Q3 2026 filing reveals a concerning cash burn, with cash and cash equivalents dropping to $1.4 million from $4.1 million at the end of 2025. This significant decline, c…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 75
Pulmatrix shares are trading higher after its proposed merger partner Eos SENOLYTIX reported encouraging PTC-2105 data addressing GLP-1-related muscle loss.
This headline indicates a significant positive catalyst for Pulmatrix, as the encouraging data from Eos SENOLYTIX's PTC-2105 drug candidate directly impacts the value proposition o…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Pulmatrix (PULM) announced its Q2 earnings, reporting a loss of $(0.29) per share. This represents a 30.95% improvement compared to the $(0.42) loss per share in the prior year's s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.